JP2021514665A5 - - Google Patents

Info

Publication number
JP2021514665A5
JP2021514665A5 JP2020547001A JP2020547001A JP2021514665A5 JP 2021514665 A5 JP2021514665 A5 JP 2021514665A5 JP 2020547001 A JP2020547001 A JP 2020547001A JP 2020547001 A JP2020547001 A JP 2020547001A JP 2021514665 A5 JP2021514665 A5 JP 2021514665A5
Authority
JP
Japan
Prior art keywords
item
cells
enucleated
polypeptide
exogenous
Prior art date
Application number
JP2020547001A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021514665A (ja
JPWO2019173798A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/021490 external-priority patent/WO2019173798A1/en
Publication of JP2021514665A publication Critical patent/JP2021514665A/ja
Publication of JP2021514665A5 publication Critical patent/JP2021514665A5/ja
Publication of JPWO2019173798A5 publication Critical patent/JPWO2019173798A5/ja
Pending legal-status Critical Current

Links

JP2020547001A 2018-03-08 2019-03-08 がんおよび感染症を処置するための治療用細胞系および方法 Pending JP2021514665A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201862640530P 2018-03-08 2018-03-08
US62/640,530 2018-03-08
US201862660657P 2018-04-20 2018-04-20
US62/660,657 2018-04-20
US201862680490P 2018-06-04 2018-06-04
US62/680,490 2018-06-04
US201862692487P 2018-06-29 2018-06-29
US62/692,487 2018-06-29
US201862732050P 2018-09-17 2018-09-17
US62/732,050 2018-09-17
US201862757717P 2018-11-08 2018-11-08
US62/757,717 2018-11-08
PCT/US2019/021490 WO2019173798A1 (en) 2018-03-08 2019-03-08 Therapeutic cell systems and methods for treating cancer and infectious diseases

Publications (3)

Publication Number Publication Date
JP2021514665A JP2021514665A (ja) 2021-06-17
JP2021514665A5 true JP2021514665A5 (https=) 2022-03-16
JPWO2019173798A5 JPWO2019173798A5 (https=) 2022-03-16

Family

ID=65904565

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020547001A Pending JP2021514665A (ja) 2018-03-08 2019-03-08 がんおよび感染症を処置するための治療用細胞系および方法

Country Status (12)

Country Link
US (2) US11141433B2 (https=)
EP (1) EP3762422A1 (https=)
JP (1) JP2021514665A (https=)
KR (1) KR20200140279A (https=)
CN (1) CN112105723A (https=)
AU (1) AU2019232012A1 (https=)
CA (1) CA3093387A1 (https=)
IL (1) IL277159A (https=)
MX (1) MX2020009359A (https=)
RU (1) RU2020132924A (https=)
SG (1) SG11202008261WA (https=)
WO (1) WO2019173798A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
AU2018316166A1 (en) 2017-08-07 2020-02-06 The Regents Of The University Of California Platform for generating safe cell therapeutics
EP3762422A1 (en) 2018-03-08 2021-01-13 Rubius Therapeutics, Inc. Therapeutic cell systems and methods for treating cancer and infectious diseases
JP2022513705A (ja) * 2018-12-03 2022-02-09 ルビウス セラピューティクス, インコーポレイテッド Hla-eおよびhla-g分子を含む人工抗原提示細胞、ならびに使用の方法
JP2022530130A (ja) 2019-04-26 2022-06-27 ルビウス セラピューティクス, インコーポレイテッド 除核赤血球細胞を含む緩衝組成物
US20220241375A1 (en) 2019-05-20 2022-08-04 Cytune Pharma Il-2/il-15r beta gamma agonist dosing regimens for treating cancer or infectious diseases
CN110777115B (zh) * 2019-11-21 2020-08-21 北京启辰生生物科技有限公司 用于促进辅助T细胞产生TNF-α细胞因子的工程化DC细胞及方法
CN115397395A (zh) * 2020-02-07 2022-11-25 加利福尼亚大学董事会 生物工程去核细胞的方法和用途
CN115151636A (zh) * 2020-02-10 2022-10-04 鲁比厄斯治疗法股份有限公司 包含hla-g多肽的经工程改造的红系细胞及其使用方法
CN111849896B (zh) * 2020-07-31 2022-07-01 广东昭泰体内生物医药科技有限公司 一种car-nk细胞培养基及其应用
EP4232069A1 (en) 2020-10-26 2023-08-30 Cytune Pharma Il-2/il-15rbetagamma agonist for treating squamous cell carcinoma
MX2023004880A (es) 2020-10-26 2023-05-11 Cytune Pharma AGONISTA DE IL-2/IL-15RßY PARA EL TRATAMIENTO DE CÁNCER DE PIEL QUE NO ES MELANOMA.
TW202241471A (zh) 2021-01-08 2022-11-01 美商盧比亞斯治療公司 提高個體中NKp30陽性淋巴球的方法及其用途
TW202241470A (zh) 2021-01-08 2022-11-01 美商盧比亞斯治療公司 治療人類個體腫瘤之方法
WO2022197548A1 (en) 2021-03-14 2022-09-22 Rubius Therapeutics, Inc. Methods of increasing nkg2d-positive lymphocytes in a subject and uses thereof
KR102829749B1 (ko) * 2021-06-01 2025-07-07 주식회사 박셀바이오 배양보조세포를 포함하는 자연살해세포 증식용 조성물
TW202317179A (zh) 2021-06-03 2023-05-01 美商盧比亞斯治療公司 在個體中治療hpv16-陽性或hpv16-相關的癌症之方法
CN115595310A (zh) * 2021-07-08 2023-01-13 中国医学科学院血液病医院(中国医学科学院血液学研究所)(Cn) Nk细胞的滋养细胞、其制备方法和应用
CN113599395B (zh) * 2021-09-22 2022-08-12 郑州源创吉因实业有限公司 含有nk细胞的治疗癌症的药物组合物
CN114113639B (zh) * 2022-01-29 2022-04-19 北京大有天弘科技有限公司 一种血型抗体检测方法及其应用
WO2023250484A2 (en) * 2022-06-24 2023-12-28 Emory University Recombinant interleukin-37, chimeric antigen receptors, nucleic acids, and vectors encoding the same and uses in cancer therapies
KR20250139902A (ko) * 2022-12-28 2025-09-23 사이토누스 테라퓨틱스, 인크. 암 치료용 조성물 및 방법
EP4694916A1 (en) 2023-04-14 2026-02-18 SOTIO Biotech Inc. Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists
CN116789795A (zh) * 2023-06-21 2023-09-22 广州奥科生物医学科技有限公司 一种将外源过表达蛋白锚定细胞膜上的多肽及应用
CN117304343B (zh) * 2023-10-11 2024-05-07 北京景达生物科技有限公司 Gpc3靶向的car-nk细胞的制备及其应用
WO2025221669A1 (en) * 2024-04-18 2025-10-23 Promab Biotechnologies, Inc. Fusion protein comprising il-12 and gm-csf

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327710A (en) 1980-06-18 1982-05-04 The United States Of America As Represented By The Secretary Of Agriculture Process for encapsulating additives in resealed erythrocytes for disseminating chemicals via the circulatory system
US4935223A (en) 1988-08-04 1990-06-19 Board Of Regents, The University Of Texas System Labeled cells for use in imaging
DE69127615T2 (de) 1991-06-14 1998-03-19 Europ Communities Transformierte Erythrozyten, Verfahren zu deren Herstellung, und ihre Verwendung in pharmazeutischen Zusammensetzungen
EP0882448B1 (en) 1997-05-05 2005-01-12 DIDECO S.r.l. Method of encapsulating biologically active agents within erythrocytes and apparatus therefor
US6495351B2 (en) 2000-02-08 2002-12-17 Gendel Limited Loading system and method for using the same
DE10335833A1 (de) * 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
EP2366787B1 (en) * 2006-01-13 2019-12-11 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Codon optimized IL-15 and IL-15R-Alpha genes for expression in mammalian cells
US20070243137A1 (en) 2006-04-18 2007-10-18 Nanoprobes, Inc. Cell and sub-cell methods for imaging and therapy
NZ582330A (en) * 2007-06-27 2012-05-25 Marinepolymer Tech Inc COMPLEXES OF IL-15 AND IL-15Ra (RECEPTOR ALPHA) AND USES THEREOF
FR2919804B1 (fr) * 2007-08-08 2010-08-27 Erytech Pharma Composition et vaccin therapeutique anti-tumoral
US20100040546A1 (en) 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
PT2614082T (pt) 2010-09-09 2018-12-03 Pfizer Moléculas de ligação a 4-1bb
WO2012129109A2 (en) 2011-03-18 2012-09-27 New York Blood Center, Inc. Megakaryocyte and platelet production from stem cells
EP3546484B1 (en) 2013-05-10 2021-09-08 Whitehead Institute for Biomedical Research In vitro production of red blood cells with sortaggable proteins
US10260038B2 (en) 2013-05-10 2019-04-16 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
AU2014348683B2 (en) 2013-11-18 2020-11-05 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
ES2865825T3 (es) 2014-04-01 2021-10-18 Rubius Therapeutics Inc Procedimientos y composiciones para inmunomodulación
KR20160145802A (ko) * 2014-04-23 2016-12-20 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 요법에 사용하기 위한 키메라 항원 수용체 (car) 및 이의 제조 방법
SG10201913163PA (en) * 2015-12-18 2020-03-30 Oncosec Medical Inc Plasmid constructs for heterologous protein expression and methods of use
AU2017207736A1 (en) * 2016-01-11 2018-07-12 Rubius Therapeutics, Inc. Compositions and methods related to multimodal therapeutic cell systems for immune indications
KR20180096789A (ko) 2016-01-11 2018-08-29 인히브릭스, 인크. 다가 및 다중특이적 41bb-결합 융합 단백질
BR112019000195A2 (pt) 2016-07-07 2019-04-24 Rubius Therapeutics, Inc. composições e métodos relacionados a sistemas celulares terapêuticos que expressam rna exógeno
CN106755107B (zh) * 2016-11-22 2019-10-01 上海健信生物医药科技有限公司 一种car新分子及其在肿瘤治疗中的应用
KR20190091497A (ko) * 2016-12-02 2019-08-06 루비우스 테라퓨틱스, 아이엔씨. 고형 종양으로의 침투를 위한 세포 시스템과 관련된 조성물 및 방법
CN110520522A (zh) 2017-02-17 2019-11-29 鲁比厄斯治疗法股份有限公司 功能化红系细胞
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
EP3762422A1 (en) 2018-03-08 2021-01-13 Rubius Therapeutics, Inc. Therapeutic cell systems and methods for treating cancer and infectious diseases

Similar Documents

Publication Publication Date Title
JP2021514665A5 (https=)
JPWO2019173798A5 (https=)
RU2020132924A (ru) Терапевтические клеточные системы и способы лечения рака и инфекционных заболеваний
JP6709549B2 (ja) T細胞の機能増強方法
KR102719575B1 (ko) 신규의 세포 태그의 발현
JP2024138280A5 (https=)
US5962320A (en) Engineered antigen presenting cells and methods for their use
JP2019517267A5 (https=)
CN111566201A (zh) 使用用于表达嵌合抗原受体(car)或转基因t细胞受体(tcr)的病毒载体转导细胞的方法
JP2021525534A5 (https=)
RU98111622A (ru) Противоопухолевая вакцина и способ ее получения
CN114127287A (zh) 乙酰胆碱受体嵌合自身抗体受体细胞的组合物和方法
EP4041869A1 (en) Composition for reprogramming cells into plasmacytoid dendritic cells or interferon type i-producing cells, methods and uses thereof
JP2022512540A5 (https=)
JPWO2019236577A5 (https=)
CN117106061B (zh) 靶向巨细胞病毒抗原的tcr和表达其的t细胞及应用
CN114555815A (zh) T细胞受体及其使用方法
CN111499766B (zh) 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用
KR20200064107A (ko) 쥐 불변 영역을 갖는 tcr을 발현하는 세포를 선택적으로 확대시키는 방법
EP4524150A1 (en) Use of antigen short peptide in screening of drug for treating hpv-related disease, and tcr screened by antigen short peptide
WO2025082236A1 (zh) 识别ebv抗原的t细胞受体及其应用
US20250361294A1 (en) Nucleic acid sequence encoding a chimeric antigen natural killer cell receptor (nk-car), polypeptide of said nk-car, vector comprising said nucleic acid sequence, in vitro method of obtaining an nk cell, use of said nucleic acid sequence, polypeptide or vector, and pharmaceutical composition
US20220152108A1 (en) Chimeric antigen receptors directed to cells expressing the sodium taurocholate co-transporting receptor
CN117736301B (zh) 靶向巨细胞病毒pp65的TCR和表达其的T细胞及应用
WO2025055790A1 (zh) 细胞因子融合蛋白及其应用